

Latent Toxoplasma infection (N=145)			Multivariate Model 1					Multivariate Model 2			Multivariate Model 3				
	TATA- (N=35. 24.1%)	TATA+ (N=110. 75.9%)	global symptomatology					Specific symptoms			Peripheral inflammation				
N or mean (% or SD)	N or mean (% or SD)	N or mean (% or SD)	P value	aOR R	IC95 %	IC9 5%	adjusted p value	aOR	IC9 5%	IC9 5%	adjusted p value	aOR	IC9 5%	IC9 5%	adjusted p value

Sociodemographic and illness variables

Addictions

Current cannabis use disorder	9	6.2%	1	2.9%	8	7.3%	0.34
Current alcohol use disorder	13	9.0%	3	8.6%	10	9.1%	0.92
Current daily tobacco smoking	79	55.2%	16	47.1%	63	57.8%	0.27

Clinical symptomatology

PANSS total score	73.1	21.2	74.8	18.6	72.5	22.0	0.55
PANSS positive subscore	9.5	4.5	9.1	4.4	9.6	4.6	0.60
PANSS negative subscore	17.5	6.9	17.8	6.5	17.4	7.1	0.74
PANSS disorganized subscore	8.6	4.1	8.3	4.1	8.7	4.1	0.47
PANSS excited subscore	5.7	2.3	5.9	1.9	5.7	2.4	0.24

PANSS depressive subscore	7.9	3.4	9.0	3.6	7.6	3.3	0.08	0.8	0.7	0.9	0.01
Suicide attempt in the last 12 months	4	2.9%	1	3.0%	3	2.9%	0.97				
Number of lifetime psychotic episodes	3.0	2.7	3.0	2.5	3.0	2.7	0.83				
Number of lifetime thymic episodes	1.7	2.6	1.5	2.5	1.8	2.7	0.18				
Paranoid delusion	59	47.2%	12	40.0%	47	49.5%	0.36				
Reference delusion	32	25.8%	4	14.3%	28	28.9%	0.11	0.1	0.1	0.6	0.14
Grandiosity delusion	12	9.4%	6	20.0%	6	6.1%	0.02	0.2	0.0	1.2	0.09
Somatic delusion	18	14.0	5	16.7%	13	13.1%	0.62				
Mystic delusion	15	11.5%	4	13.8%	11	10.8%	0.65				
Auditory hallucinations	41	32.5%	7	23.3%	34	35.4%	0.21				
Cenesthetic hallucinations	25	19.4%	9	30.0%	16	16.2%	0.09	0.5	0.1	1.9	0.27
Visual hallucinations	22	16.9%	8	26.7%	14	14.0%	0.10	0.2	0.0	1.1	0.07
Desorganized behavior	15	11.6%	6	19.4%	9	9.2%	0.12	0.7	0.1	3.9	0.71
Blunted affect	64	52.9%	16	57.1%	48	51.6%	0.60				
Alogia	42	34.1%	10	35.7%	32	33.7%	0.84				
Avolia	75	59.5%	21	72.4%	54	55.7%	0.10	0.4	0.1	1.1	0.07
Chronic peripheral inflammation (hsCRP≥3 mg/L)	40	27.6%	17	48.6%	23	20.9%	0.001			3.5	1.5
											7.9
											0.003

Treatments

Chlorpromazine equivalent	622.4	653.6	482.4	309.2	661.8	717.9	0.83
Extrapyramidal symptoms	0.3	0.4	0.2	0.3	0.3	0.5	0.31
Antidepressants	53	36.6%	11	31.4%	42	38.2%	0.47
Benzodiazepine	38	26.2%	9	25.7%	29	26.4%	0.93

Table 2. Associations between Treatment with Anti-Toxoplasmic Activity (TATA), clinical characteristics and peripheral inflammation in a sample of 145 community-dwelling stabilized outpatients with schizophrenia and latent Toxoplasmic infection. Univariate and multivariate analyses. Extrapyramidal symptoms were measured with the Simpson and Angus scale.

Significant associations are in bold.

PANSS Positive and negative Syndrome Scale. FGA First Generation Antipsychotic. SGA second generation antipsychotic. CPZeq Chlorpromazine equivalent.

\$